Age-related white matter changes in Asia

Neurology Asia

Volumn 16, Issue 3, 2011, Pages 179-186

  Xiong, Yun Yun ^a   Mok, Vincent ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; C REACTIVE PROTEIN; CHOLINESTERASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDAPAMIDE; INTERCELLULAR ADHESION MOLECULE 1; MEMANTINE; MYELOPEROXIDASE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PERINDOPRIL; PLACEBO; PRAVASTATIN; RIVASTIGMINE; SIMVASTATIN;

AGE; ANOREXIA; ASIA; BRAIN ATHEROSCLEROSIS; CLINICAL FEATURE; COGNITIVE DEFECT; CONTROLLED STUDY; DEATH; DEPRESSION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DOPPLER ECHOGRAPHY; DRUG EFFICACY; DRUG SAFETY; GAIT DISORDER; HUMAN; IMAGE ANALYSIS; IMAGE DISPLAY; LEG CRAMP; MULTIINFARCT DEMENTIA; NAUSEA; NEUROIMAGING; OUTCOME ASSESSMENT; PATHOGENESIS; PHENOTYPE; PREVALENCE; REVIEW; STROKE; URINE INCONTINENCE; VOMITING; WHITE MATTER;

EID: 80053549828     PISSN: 18236138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (102)

1. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 2010; 9:689-701.
2. Kohara K, Fujisawa M, Ando F, et al. MTHFR gene polymorphism as a risk factor for silent brain infarcts and white matter lesions in the Japanese general population: The NILS-LSA Study. Stroke 2003; 34:1130-5.
3. Park MK, Jo I, Park MH, Kim TK, Jo SA, Shin C. Cerebral white matter lesions and hypertension status in the elderly Korean: the Ansan Study. Arch Gerontol Geriatr 2005; 40:265-73.
4. Choi HS, Cho YM, Kang JH, Shin CS, Park KS, Lee HK. Cerebral white matter hyperintensity is mainly associated with hypertension among the components of metabolic syndrome in Koreans. Clin Endocrinol (Oxf) 2009; 71:184-8.
5. Wen HM, Mok VC, Fan YH, et al. Effect of white matter changes on cognitive impairment in patients with lacunar infarcts. Stroke 2004; 35:1826-30.
6. de Leeuw FE, de Groot JC, Achten E, et al. Prevalence of cerebral white matter lesions in elderly people: a population based magnetic resonance imaging study. The Rotterdam Scan Study. J Neurol Neurosurg Psychiatry 2001; 70:9-14.
7. Schmidt R, Scheltens P, Erkinjuntti T, et al. White matter lesion progression: a surrogate endpoint for trials in cerebral small-vessel disease. Neurology 2004; 63:139-44.
8. Schmidt R, Enzinger C, Ropele S, Schmidt H, Fazekas F. Progression of cerebral white matter lesions: 6-year results of the Austrian Stroke Prevention Study. Lancet 2003; 361:2046-8.
9. van Dijk EJ, Prins ND, Vrooman HA, Hofman A, Koudstaal PJ, Breteler MM. Progression of cerebral small vessel disease in relation to risk factors and cognitive consequences: Rotterdam Scan study. Stroke 2008; 39:2712-9.
10. Mok VC, Lam WW, Fan YH, et al. Effects of statins on the progression of cerebral white matter lesion: Post hoc analysis of the ROCAS (Regression of Cerebral Artery Stenosis) study. J Neurol 2009; 256:750-7.
11. Brun A, Englund E. A white matter disorder in dementia of the Alzheimer type: a pathoanatomical study. Ann Neurol 1986; 19:253-62.
12. Pantoni L. Pathophysiology of age-related cerebral white matter changes. Cerebrovasc Dis 2002; 13 (Suppl 2):7-10.
13. Pantoni L, Inzitari D, Pracucci G, et al. Cerebrospinal fluid proteins in patients with leucoaraiosis: possible abnormalities in blood-brain barrier function. J Neurol Sci 1993; 115:125-31.
14. Wallin A, Sjogren M, Edman A, Blennow K, Regland B. Symptoms, vascular risk factors and blood-brain barrier function in relation to CT white-matter changes in dementia. Eur Neurol 2000; 44:229-35.
15. Topakian R, Barrick TR, Howe FA, Markus HS. Blood-brain barrier permeability is increased in normal-appearing white matter in patients with lacunar stroke and leucoaraiosis. J Neurol Neurosurg Psychiatry 2010; 81:192-7.
16. Fu JH, Lu CZ, Hong Z, Dong Q, Ding D, Wong KS. Relationship between cerebral vasomotor reactivity and white matter lesions in elderly subjects without large artery occlusive disease. J Neuroimaging 2006; 16:120-5.
17. Isaka Y, Okamoto M, Ashida K, Imaizumi M. Decreased cerebrovascular dilatory capacity in subjects with asymptomatic periventricular hyperintensities. Stroke 1994; 25:375-81.
18. Bakker SL, de Leeuw FE, de Groot JC, Hofman A, Koudstaal PJ, Breteler MM. Cerebral vasomotor reactivity and cerebral white matter lesions in the elderly. Neurology 1999; 52:578-83.
19. Kozera GM, Dubaniewicz M, Zdrojewski T, et al. Cerebral Vasomotor Reactivity and Extent of White Matter Lesions in Middle-Aged Men With Arterial Hypertension: A Pilot Study. Am J Hypertens 2010; 23 11:1198-203.
20. Chung CP, Hu HH. Pathogenesis of leukoaraiosis: role of jugular venous reflux. Med Hypotheses 2010; 75:85-90.
21. Pantoni L, Garcia JH. Pathogenesis of leukoaraiosis: a review. Stroke 1997; 28:652-9.
22. Brown WR, Moody DM, Thore CR, Challa VR. Apoptosis in leukoaraiosis. AJNR Am J Neuroradiol 2000; 21:79-82.
23. Jickling G, Salam A, Mohammad A, et al. Circulating endothelial progenitor cells and age-related white matter changes. Stroke 2009; 40:3191-6.
24. Hassan A, Hunt BJ, O'Sullivan M, et al. Markers of endothelial dysfunction in lacunar infarction and ischaemic leukoaraiosis. Brain 2003; 126:424-32.
25. Fazekas F, Kleinert R, Offenbacher H, et al. Pathologic correlates of incidental MRI white matter signal hyperintensities. Neurology 1993; 43:1683-9.
26. Simpson JE, Ince PG, Higham CE, et al. Microglial activation in white matter lesions and nonlesional white matter of ageing brains. Neuropathol Appl Neurobiol 2007; 33:670-83.
27. Carmelli D, DeCarli C, Swan GE, et al. Evidence for genetic variance in white matter hyperintensity volume in normal elderly male twins. Stroke 1998; 29:1177-81.
28. de Leeuw FE, Richard F, de Groot JC, et al. Interaction between hypertension, apoE, and cerebral white matter lesions. Stroke 2004; 35:1057-60.
29. Henskens LH, Kroon AA, van Boxtel MP, Hofman PA, de Leeuw PW. Associations of the angiotensin II type 1 receptor A1166C and the endothelial NO synthase G894T gene polymorphisms with silent subcortical white matter lesions in essential hypertension. Stroke 2005; 36:1869-73.
30. Paternoster L, Chen W, Sudlow CL. Genetic determinants of white matter hyperintensities on brain scans: a systematic assessment of 19 candidate gene polymorphisms in 46 studies in 19,000 subjects. Stroke 2009; 40:2020-6.
31. Wen HM, Baum L, Cheung WS, et al. Apolipoprotein E epsilon4 allele is associated with the volume of white matter changes in patients with lacunar infarcts. Eur J Neurol 2006; 13: 1216-20.
32. Hong YJ, Yoon B, Shim YS, et al. APOE epsilon4 allele status in korean dementia patients with severe white matter hyperintensities. J Alzheimers Dis 2011; 24:519-24.
33. Fazekas F, Barkhof F, Wahlund LO, et al. CT and MRI rating of white matter lesions. Cerebrovasc Dis 2002; 13 (Suppl 2):31-6.
34. Wahlund LO, Barkhof F, Fazekas F, et al. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 2001; 32:1318-22.
35. Hachinski V, Iadecola C, Petersen RC, et al. National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke 2006; 37:2220-41.
36. Xiong Y, Mok V, Wong A, et al. The age-related white matter changes scale correlates with cognitive impairment. Eur J Neurol 2010; 17:1451-6.
37. Xiong Y, Yang J, Wong A, et al. Operational definitions improve reliability of the age-related white matter changes scale. Eur J Neurol 2010; 18:744-9.
38. Xiong Y Y, Mok V, Wong A, et al. Evaluation of age-related white matter changes using transcranial Doppler ultrasonography. J Neuroimaging 2011 Sep 1. doi: 10.1111/j.1552-6569.2011.00639.x. [Epub ahead of print]
39. Anan F, Masaki T, Tatsukawa H, et al. The role of homocysteine as a significant risk factor for white matter lesions in Japanese women with rheumatoid arthritis. Metabolism 2009; 58:69-73.
40. Wright CB, Paik MC, Brown TR, et al. Total homocysteine is associated with white matter hyperintensity volume: the Northern Manhattan Study. Stroke 2005; 36:1207-11.
41. Vermeer SE, van Dijk EJ, Koudstaal PJ, et al. Homocysteine, silent brain infarcts, and white matter lesions: The Rotterdam Scan Study. Ann Neurol 2002; 51:285-9.
42. Wong A, Mok V, Fan YH, Lam WW, Liang KS, Wong KS. Hyperhomocysteinemia is associated with volumetric white matter change in patients with small vessel disease. J Neurol 2006; 253:441-7.
43. Markus HS, Hunt B, Palmer K, Enzinger C, Schmidt H, Schmidt R. Markers of endothelial and hemostatic activation and progression of cerebral white matter hyperintensities: longitudinal results of the Austrian Stroke Prevention Study. Stroke 2005; 36:1410-4.
44. Han JH, Wong KS, Wang YY, Fu JH, Ding D, Hong Z. Plasma level of sICAM-1 is associated with the extent of white matter lesion among asymptomatic elderly subjects. Clin Neurol Neurosurg 2009; 111:847-51.
45. Schmidt R, Schmidt H, Pichler M, et al. C-reactive protein, carotid atherosclerosis, and cerebral small-vessel disease: results of the Austrian Stroke Prevention Study. Stroke 2006; 37:2910-6.
46. van Dijk EJ, Prins ND, Vermeer SE, et al. C-reactive protein and cerebral small-vessel disease: the Rotterdam Scan Study. Circulation 2005; 112:900-5.
47. Fornage M, Chiang YA, O'Meara ES, et al. Biomarkers of infl ammation and MRI-defi ned small vessel disease of the brain: The Cardiovascular Health Study. Stroke 2008; 39:1952-9.
48. Wright CB, Moon Y, Paik MC, et al. Infl ammatory biomarkers of vascular risk as correlates of leukoariosis. Stroke 2009; 40:3466-71.
49. Prins ND, van Dijk EJ, den Heijer T, et al. Cerebral small-vessel disease and decline in information processing speed, executive function and memory. Brain 2005; 128:2034-41.
50. de Groot JC, de Leeuw FE, Oudkerk M, et al. Cerebral white matter lesions and cognitive function: the Rotterdam Scan Study. Ann Neurol 2000; 47:145-51.
51. Junque C, Pujol J, Vendrell P, et al. Leuko-araiosis on magnetic resonance imaging and speed of mental processing. Arch Neurol 1990; 47:151-6.
52. Ylikoski R, Ylikoski A, Erkinjuntti T, Sulkava R, Raininko R, Tilvis R. White matter changes in healthy elderly persons correlate with attention and speed of mental processing. Arch Neurol 1993; 50:818-24.
53. Longstreth WT, Jr., Manolio TA, Arnold A, et al. Clinical correlates of white matter fi ndings on cranial magnetic resonance imaging of 3301 elderly people. The Cardiovascular Health Study. Stroke 1996; 27:1274-82.
54. van der Flier WM, van Straaten EC, Barkhof F, et al. Small vessel disease and general cognitive function in nondisabled elderly: the LADIS study. Stroke 2005; 36:2116-20.
55. Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ 2010; 341:c3666
56. Schmidt R, Ropele S, Enzinger C, et al. White matter lesion progression, brain atrophy, and cognitive decline: the Austrian stroke prevention study. Ann Neurol 2005; 58:610-6.
57. Mungas D, Reed BR, Jagust WJ, et al. Volumetric MRI predicts rate of cognitive decline related to AD and cerebrovascular disease. Neurology 2002; 59:867-73.
58. Mungas D, Harvey D, Reed BR, et al. Longitudinal volumetric MRI change and rate of cognitive decline. Neurology 2005; 65:565-71.
59. Mok V, Wong KK, Xiong Y, et al. Cortical and frontal atrophy are associated with cognitive impairment in age-related confluent white-matter lesion. J Neurol Neurosurg Psychiatry 2011; 82:52-7.
60. Baezner H, Blahak C, Poggesi A, et al. Association of gait and balance disorders with age-related white matter changes: the LADIS study. Neurology 2008; 70:935-42.
61. Whitman GT, Tang Y, Lin A, Baloh RW. A prospective study of cerebral white matter abnormalities in older people with gait dysfunction. Neurology 2001; 57:990-4.
62. Srikanth V, Beare R, Blizzard L, et al. Cerebral white matter lesions, gait, and the risk of incident falls: a prospective population-based study. Stroke 2009; 40:175-80.
63. Iseki K, Hanakawa T, Hashikawa K, et al. Gait disturbance associated with white matter changes: a gait analysis and blood flow study. Neuroimage 2010; 49:1659-66.
64. Srikanth V, Phan TG, Chen J, Beare R, Stapleton JM, Reutens DC. The location of white matter lesions and gait--a voxel-based study. Ann Neurol 2010; 67:265-9.
65. Kuo HK, Lipsitz LA. Cerebral white matter changes and geriatric syndromes: is there a link? J Gerontol A Biol Sci Med Sci 2004; 59:818-26.
66. Kuchel GA, Moscufo N, Guttmann CR, et al. Localization of brain white matter hyperintensities and urinary incontinence in community-dwelling older adults. J Gerontol A Biol Sci Med Sci 2009; 64:902-9.
67. Sonohara K, Kozaki K, Akishita M, et al. White matter lesions as a feature of cognitive impairment, low vitality and other symptoms of geriatric syndrome in the elderly. Geriatr Gerontol Int 2008; 8:93-100.
68. Poggesi A, Pracucci G, Chabriat H, et al. Urinary complaints in nondisabled elderly people with age-related white matter changes: the Leukoaraiosis And DISability (LADIS) Study. J Am Geriatr Soc 2008; 56:1638-43.
69. Sitoh YY, Sitoh Y Y, Sahadevan S. Clinical significance of cerebral white matter lesions in older Asians with suspected dementia. Age Ageing 2004; 33:67-71.
70. Tadic SD, Griffiths D, Murrin A, Schaefer W, Aizenstein HJ, Resnick NM. Brain activity during bladder filling is related to white matter structural changes in older women with urinary incontinence. Neuroimage 2010; 51:1294-302.
71. Lesser IM, Hill-Gutierrez E, Miller BL, Boone KB. Late-onset depression with white matter lesions. Psychosomatics 1993; 34:364-7.
72. Nebes RD, Reynolds CF, 3rd, Boada F, et al. Longitudinal increase in the volume of white matter hyperintensities in late-onset depression. Int J Geriatr Psychiatry 2002; 17:526-30.
73. Steffens DC, Bosworth HB, Provenzale JM, MacFall JR. Subcortical white matter lesions and functional impairment in geriatric depression. Depress Anxiety 2002; 15:23-8.
74. Taylor WD, Steffens DC, MacFall JR, et al. White matter hyperintensity progression and late-life depression outcomes. Arch Gen Psychiatry 2003; 60:1090-6.
75. Teodorczuk A, O'Brien JT, Firbank MJ, et al. White matter changes and late-life depressive symptoms: longitudinal study. Br J Psychiatry 2007; 191:212-7.
76. Godin O, Dufouil C, Maillard P, et al. White matter lesions as a predictor of depression in the elderly: the 3C-Dijon study. Biol Psychiatry 2008; 63:663-9.
77. Herrmann LL, Le Masurier M, Ebmeier KP. White matter hyperintensities in late life depression: a systematic review. J Neurol Neurosurg Psychiatry 2008; 79:619-24.
78. Vattakatuchery JJ, Joy J. Hyperintensities on MRI. White matter and depression. BMJ 2010; 341:c4611.
79. Olesen PJ, Gustafson DR, Simoni M, et al. Temporal lobe atrophy and white matter lesions are related to major depression over 5 years in the elderly. Neuropsychopharmacology 2010; 35:2638-45.
80. Tang WK, Chen YK, Lu J Y, et al. White matter hyperintensities in post-stroke depression: a case control study. J Neurol Neurosurg Psychiatry 2010; 81:1312-5.
81. Fu JH, Wong K, Mok V, et al. Neuroimaging predictors for depressive symptoms in cerebral small vessel disease. Int J Geriatr Psychiatry 2010; 25:1039-43.
82. Vermeer SE, Hollander M, van Dijk EJ, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study. Stroke 2003; 34:1126-9.
83. Fu JH, Lu CZ, Hong Z, Dong Q, Luo Y, Wong KS. Extent of white matter lesions is related to acute subcortical infarcts and predicts further stroke risk in patients with fi rst ever ischaemic stroke. J Neurol Neurosurg Psychiatry 2005; 76:793-6.
84. Buyck JF, Dufouil C, Mazoyer B, et al. Cerebral white matter lesions are associated with the risk of stroke but not with other vascular events: the 3-City Dijon Study. Stroke 2009; 40:2327-31.
85. Bokura H, Kobayashi S, Yamaguchi S, et al. Silent brain infarction and subcortical white matter lesions increase the risk of stroke and mortality: a prospective cohort study. J Stroke Cerebrovasc Dis 2006; 15:57-63.
86. Oksala NK, Oksala A, Pohjasvaara T, et al. Age related white matter changes predict stroke death in long term follow-up. J Neurol Neurosurg Psychiatry 2009; 80:762-6.
87. Inzitari D, Cadelo M, Marranci ML, Pracucci G, Pantoni L. Vascular deaths in elderly neurological patients with leukoaraiosis. J Neurol Neurosurg Psychiatry 1997; 62:177-81.
88. Mok VC, Lau AY, Wong A, et al. Long-term prognosis of Chinese patients with a lacunar infarct associated with small vessel disease: a five-year longitudinal study. Int J Stroke 2009; 4:81-8.
89. Palumbo V, Boulanger JM, Hill MD, Inzitari D, Buchan AM. Leukoaraiosis and intracerebral hemorrhage after thrombolysis in acute stroke. Neurology 2007; 68:1020-4.
90. Lee SH, Kim BJ, Ryu WS, et al. White matter lesions and poor outcome after intracerebral hemorrhage: a nationwide cohort study. Neurology 2010; 74:1502-10.
91. Dufouil C, Chalmers J, Coskun O, et al. Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke: the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy. Circulation 2005; 112:1644-50.
92. Pantoni L, Garcia JH. The significance of cerebral white matter abnormalities 100 years after Binswanger's report. A review. Stroke 1995; 26:1293-301.
93. Kario K, Matsuo T, Kobayashi H, Imiya M, Matsuo M, Shimada K. Nocturnal fall of blood pressure and silent cerebrovascular damage in elderly hypertensive patients. Advanced silent cerebrovascular damage in extreme dippers. Hypertension 1996; 27:130-5.
94. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-9.
95. Bernick C, Katz R, Smith NL, et al. Statins and cognitive function in the elderly: the Cardiovascular Health Study. Neurology 2005; 65:1388-94.
96. Jimenez-Conde J, Biffi A, Rahman R, et al. Hyperlipidemia and reduced white matter hyperintensity volume in patients with ischemic stroke. Stroke 2010; 41:437-42.
97. Woo D, Kissela BM, Khoury JC, et al. Hypercholesterolemia, HMG-CoA reductase inhibitors, and risk of intracerebral hemorrhage: a case-control study. Stroke 2004; 35:1360-4.
98. Roquer J, Rodriguez Campello A, Gomis M, Ois A, Munteis E, Bohm P. Serum lipid levels and in-hospital mortality in patients with intracerebral hemorrhage. Neurology 2005; 65:1198-202.
99. Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol 2007; 6:782-92.
100. Mobius HJ, Stoffler A. New approaches to clinical trials in vascular dementia: memantine in small vessel disease. Cerebrovasc Dis 2002; 13 (Suppl 2):61-6.
101. Mok V, Wong A, Ho S, Leung T, Lam WW, Wong KS. Rivastigmine in Chinese patients with subcortical vascular dementia. Neuropsychiatr Dis Treat 2007; 3:943-8.
102. Narasimhalu K, Effendy S, Sim CH, et al. A randomized controlled trial of rivastigmine in patients with cognitive impairment no dementia because of cerebrovascular disease. Acta Neurol Scand 2010; 121:217-24.